Cue Biopharma Inc (NAS:CUE)
$ 1.635 -0.015 (-0.91%) Market Cap: 79.53 Mil Enterprise Value: 51.74 Mil PE Ratio: 0 PB Ratio: 2.64 GF Score: 52/100

Q4 2020 Cue Biopharma Inc Earnings Call Transcript

Mar 16, 2021 / 08:30PM GMT
Release Date Price: $14.82 (-1.92%)
Operator

Greetings. Welcome to Cue Biopharma Fourth Quarter and Full Year 2020 Earnings Call. (Operator Instructions) Please note, this conference is being recorded.

I would now turn the conference over to Dr. George Zavoico, Vice President of IR and Corporate Development. Thank you. You may begin.

George B. Zavoico
Cue Biopharma, Inc. - VP of IR & Corporate Development

Thanks, Sherry, and good afternoon, everyone. Thank you for joining us. On today's call are Dan Passeri, Cue Biopharma's CEO; Dr. Anish Suri, President and Chief Scientific Officer; Dr. Ken Pienta, Chief Medical Officer; Dr. Matteo Levisetti, Senior Vice President of Clinical Development; and Kerri-Ann Millar, Chief Financial Officer.

Before we begin, I would like to remind you that various remarks that the company makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot